7 news items
Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference
GOSS
14 May 24
for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GOSS
10 May 24
for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary
Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GOSS
7 May 24
for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary
Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications
GOSS
6 May 24
on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal is to be an industry leader in, and to enhance
Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine
GOSS
3 May 24
biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary hypertension. Its goal
4chjf
GOSS
12 Mar 24
arterial hypertension. Its goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension
x7kstw7kh4d4vbbk7ky
GOSS
5 Mar 24
goal is to be an industry leader in, and to enhance the lives of patients suffering from, pulmonary hypertension
- Prev
- 1
- Next